Sionna Therapeutics, Inc. (SION)
NASDAQ:SION
Want to see SION full AI Analyst Report?
Top Page
Sionna Therapeutics, Inc.
(NASDAQ:SION)
Select Model
Select Model
Rating:55Neutral
Price Target:
$37.00
▼(-15.02% Downside)
Action:Reiterated
Date:04/16/26
The score is held back mainly by weak financial performance (no revenue, widening losses, and increasing cash burn), partially mitigated by a much stronger 2025 balance sheet and low leverage. Technicals are a meaningful positive, with the stock above key moving averages and positive momentum indicators, while valuation remains pressured due to losses and a negative P/E.
Positive Factors
Targeted CFTR small-molecule pipeline
Sionna’s business model is concentrated on small-molecule therapies that target underlying CFTR protein dysfunction in cystic fibrosis. This disease-modifying focus addresses an enduring unmet medical need and positions the company in a structurally attractive niche where successful candidates can secure long-term demand and durable clinical value.
Negative Factors
Heavy and rising cash burn
Persistent and increasing operating cash outflows (OCF -$66.3M in 2025) create ongoing funding pressure for a company with no product revenue. Over a multi-month horizon, rising burn magnifies the need for external financing and heightens execution risk if clinical timelines slip or additional capital cannot be secured on favorable terms.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted CFTR small-molecule pipeline
Sionna’s business model is concentrated on small-molecule therapies that target underlying CFTR protein dysfunction in cystic fibrosis. This disease-modifying focus addresses an enduring unmet medical need and positions the company in a structurally attractive niche where successful candidates can secure long-term demand and durable clinical value.
Read all positive factors
Sionna Therapeutics, Inc. (SION) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.62B
Dividend YieldN/A
Average Volume (3M)377.17K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue GrowthN/A
EPS Growth-27.48%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.93
Shares Outstanding45,150,330
10 Day Avg. Volume369,735
30 Day Avg. Volume377,169
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.15K
Enterprise Value/Ebitda-22.84
Forecast
1Y Price Target
$51.71Price Target Upside18.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Sionna Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal funct...
How the Company Makes Money
null...
Sionna Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -453.00K | -647.00K | -668.00K | 0.00 | 0.00 |
| EBITDA | -82.25M | -74.62M | -61.02M | -46.68M | -40.12M |
| Net Income | -85.56M | -75.27M | -61.69M | -47.26M | -40.24M |
Balance Sheet | |||||
| Total Assets | 305.04M | 325.95M | 185.75M | 51.95M | 87.37M |
| Cash, Cash Equivalents and Short-Term Investments | 216.15M | 235.88M | 147.54M | 38.52M | 82.61M |
| Total Debt | 8.38M | 8.68M | 9.75M | 10.48M | 0.00 |
| Total Liabilities | 16.83M | 19.12M | 349.46M | 166.83M | 157.29M |
| Stockholders Equity | 288.21M | 306.83M | -163.71M | -114.88M | -69.92M |
Cash Flow | |||||
| Free Cash Flow | -72.14M | -66.67M | -52.81M | -44.81M | -37.94M |
| Operating Cash Flow | -71.85M | -66.30M | -52.79M | -43.70M | -36.07M |
| Investing Cash Flow | 47.27M | -118.75M | -126.91M | 27.35M | -29.26M |
| Financing Cash Flow | 5.21M | 205.71M | 178.97M | 31.00K | 110.86M |
Sionna Therapeutics, Inc. Risk Analysis
Sionna Therapeutics, Inc. disclosed 76 risk factors in its most recent earnings report. Sionna Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sionna Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $5.04B | -41.43 | -41.54% | ― | 39.04% | 32.40% | |
58 Neutral | $1.45B | -2.87 | -53.31% | ― | 213.96% | 25.74% | |
55 Neutral | $1.62B | -18.86 | -27.31% | ― | ― | -27.48% | |
52 Neutral | $1.62B | -10.75 | -55.68% | ― | ― | 51.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $1.86B | -11.08 | -48.84% | ― | -83.20% | -439.48% | |
44 Neutral | $1.26B | -5.09 | -45.47% | ― | -72.09% | -754.83% |
* Healthcare Sector Average
SION
Sionna Therapeutics, Inc.
35.92
21.61
151.01%
STOK
Stoke Therapeutics
29.82
18.12
154.87%
VIR
Vir Biotechnology
8.61
3.37
64.31%
IMTX
Immatics
9.38
3.28
53.77%
TNGX
Tango Therapeutics
30.94
26.15
545.93%
AMLX
Amylyx Pharmaceuticals Inc
14.59
9.15
168.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.